Search for a command to run...
SMS Lifesciences India Ltd. shows a mixed performance against its peers, with notable strengths in profitability metrics but weaknesses in growth. The company is undervalued based on its PEG ratio, and while it faces challenges in revenue growth, it maintains a manageable debt level. Key peers like Cipla and Dr. Reddy's Laboratories stand out for their robust profitability and efficient operations, while companies like Sun Pharma and Divi's Laboratories appear overvalued given their high PE ratios.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
SMSLIFE | ₹1,146.70 | ₹346.68Cr | 16.22 | 7.42% | 0.55 |
SUNPHARMA | ₹1,563.35 | ₹3,75,099.26Cr | 87.59 | 17.60% | 0.04 |
DIVISLAB | ₹6,091.05 | ₹1,61,698.50Cr | 73.20 | 16.46% | - |
CIPLA | ₹1,587.60 | ₹1,28,217.27Cr | 23.73 | 22.77% | 0.01 |
TORNTPHARM | ₹3,581.55 | ₹1,21,215.77Cr | 61.53 | 24.28% | 0.57 |
DRREDDY | ₹1,280.30 | ₹1,06,835.27Cr | 15.50 | 26.86% | 0.07 |
MANKIND | ₹2,518.95 | ₹1,03,926.59Cr | 55.18 | 28.38% | 0.02 |